Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Author:
Funder
Kurdistan University Of Medical Sciences
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference122 articles.
1. Transcription factors in ferroptotic cell death;Dai;Cancer Gene Ther.,2020
2. The current knowledge concerning solid cancer and therapy;Najafi;J. Biochem. Mol. Toxicol.,2021
3. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer;Achinger-Kawecka;Nat. Commun.,2020
4. The diversification of cell death and immunity: memento mori;Legrand;Mol. Cell,2019
5. Migrating cancer stem cells—an integrated concept of malignant tumour progression;Brabletz;Nat. Rev. Cancer,2005
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations;Gynecologic Oncology;2024-05
2. Immunotherapy of Human Melanoma: Past, Present, Future;Current Medicinal Chemistry;2024-03-06
3. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies;Life Sciences;2024-02
4. WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses;Clinical and Experimental Medicine;2024-01-27
5. Tumor-educated platelets;Clinica Chimica Acta;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3